Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
40.61 USD +2.34% Intraday chart for Apellis Pharmaceuticals, Inc. -1.69% -32.16%
May. 24 Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases MT
May. 24 Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress CI

Evolution of the average Target Price on Apellis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fdabef8ce0ec2ca032d18970.1wsqkca063rvdjWiy38uEWykpU6BvWi-CQlNOYOwUaU.lW9IqbCErEK_R1CV_jpMUAj1zCW4jgWKbnwActTWHfK7XR-jmdCGPIAPYA~0b9da5942584d4c316fabc0c724044b3

Analyst Recommendations on Apellis Pharmaceuticals, Inc.

Wells Fargo Adjusts Price Target on Apellis Pharmaceuticals to $48 From $57, Maintains Equal-Weight Rating MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating MT
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating MT
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre MT
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating MT
North American Morning Briefing : Rate Doubts Keep -2- DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68 MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating MT
Needham Adjusts Price Target on Apellis Pharmaceuticals to $75 From $70, Maintains Buy Rating MT
Wells Fargo Raises Apellis Pharmaceuticals' Price Target to $62 From $54, Maintains Equalweight Rating MT
Baird Adjusts Apellis Pharmaceuticals' Price Target to $81 From $71, Maintains Outperform Rating MT
Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $106 From $67, Maintains Strong Buy Rating MT
Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $90 From $65, Maintains Buy Rating MT
Citigroup Adjusts Apellis Pharmaceuticals' Price Target to $67 From $70, Maintains Buy Rating MT
Oppenheimer Cuts Apellis Pharmaceuticals Price Target to $75 From $88, Maintains Outperform Rating MT
Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $67 From $93, Keeps Strong Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
40.61 USD
Average target price
79.5 USD
Spread / Average Target
+95.76%
High Price Target
111 USD
Spread / Highest target
+173.33%
Low Price Target
48 USD
Spread / Lowest Target
+18.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apellis Pharmaceuticals, Inc.

Wells Fargo Securities
UBS
Wedbush
Mizuho Securities
JPMorgan Chase
Jefferies & Co.
Oppenheimer
Needham & Co.
Baird
Raymond James
Goldman Sachs
Citigroup
BofA Securities
Stifel Nicolaus
HC Wainwright
Credit Suisse
Roth Capital Partners
BMO Capital
Cowen
J.P. Morgan Chase

Ratings for Apellis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APLS Stock
  4. Consensus Apellis Pharmaceuticals, Inc.